Increasing value and reducing waste in biomedical research regulation and management

被引:319
作者
Salman, Rustam Al-Shahi [1 ]
Beller, Elaine [2 ]
Kagan, Jonathan [3 ]
Hemminki, Elina [4 ]
Phillips, Robert S. [5 ]
Savulescu, Julian [6 ]
Macleod, Malcolm [1 ]
Wisely, Janet [7 ]
Chalmers, Iain [8 ]
机构
[1] Univ Edinburgh, Ctr Clin Brain Sci, Div Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland
[2] Bond Univ, Ctr Res Evidence Based Practice, Robina, Qld, Australia
[3] NIAID, Div Clin Res, Bethesda, MD 20892 USA
[4] Natl Inst Hlth & Welf, Helsinki, Finland
[5] Univ York, Ctr Reviews & Disseminat, York YO10 5DD, N Yorkshire, England
[6] Univ Oxford, Oxford Ctr Neuroeth, Oxford, England
[7] Hlth Res Author, London, England
[8] James Lind Initiat, Oxford, England
基金
英国医学研究理事会;
关键词
RESEARCH ETHICS COMMITTEES; CLINICAL-TRIALS; RESEARCH GOVERNANCE; HEALTH-CARE; RANDOMIZED-TRIALS; CHILDHOOD-CANCER; INFORMED-CONSENT; DATA QUALITY; IMPACT; UK;
D O I
10.1016/S0140-6736(13)62297-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
After identification of an important research question and selection of an appropriate study design, waste can arise from the regulation, governance, and management of biomedical research. Obtaining regulatory and governance approval has become increasingly burdensome and disproportionate to the conceivable risks to research participants. Regulation and governance involve interventions that are assumed to be justified in the interests of patients and the public, but they can actually compromise these interests. Inefficient management of the procedural conduct of research is wasteful, especially if it results in poor recruitment and retention of participants in well designed studies addressing important questions. These sources of waste can be minimised if the following four recommendations are addressed. First, regulators should use their influence to reduce other causes of waste and inefficiency in research. Second, regulators and policy makers should work with researchers, patients, and health professionals to streamline and harmonise the laws, regulations, guidelines, and processes that govern whether and how research can be done, and ensure that they are proportionate to the plausible risks associated with the research. Third, researchers and research managers should increase the efficiency of recruitment, retention, data monitoring, and data sharing in research through use of research designs known to reduce inefficiencies, and further research should be done to learn how efficiency can be increased. Finally, everyone, particularly those responsible for health-care systems, should promote integration of research into everyday clinical practice. Regulators and researchers should monitor adherence to each of these recommendations and publish metrics.
引用
收藏
页码:176 / 185
页数:10
相关论文
共 100 条
[1]  
Academy of Medical Sciences, 2011, NEW PATHW REG GOV HL
[2]   Research ethics committees in the UK - the pressure is now on research and development departments [J].
Al-Shahi, R .
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2005, 98 (10) :444-447
[3]  
[Anonymous], 1990, LANCET, V336, P846
[4]  
[Anonymous], 2010, The Routledge Companion to Ethics
[5]  
[Anonymous], GOOD MED PRACT
[6]  
[Anonymous], IMP CLIN RES EUR LEG
[7]  
[Anonymous], 20 CENTURY
[8]  
[Anonymous], 2013, GOOD MED PRACT
[9]   Ensuring trial validity by data quality assurance and diversification of monitoring methods [J].
Baigent, Colin ;
Harrell, Frank E. ;
Buyse, Marc ;
Emberson, Jonathan R. ;
Altman, Douglas G. .
CLINICAL TRIALS, 2008, 5 (01) :49-55
[10]   A systematic search for reports of site monitoring technique comparisons in clinical trials [J].
Bakobaki, Julie ;
Joffe, Nicola ;
Burdett, Sarah ;
Tierney, Jayne ;
Meredith, Sarah ;
Stenning, Sally .
CLINICAL TRIALS, 2012, 9 (06) :777-780